<sentence id="0">Chemical genetic interrogation of natural variation uncovers a molecule that is glycoactivated .</sentence>
<sentence id="1">Natural variation in human drug metabolism and target genes can cause pharmacogenetic or interindividual variation in drug sensitivity .</sentence>
<sentence id="2">We reasoned that natural pharmacogenetic variation in model organisms <scope type="spec" id="0"> <cue type="spec" id="0">could</cue> be systematically exploited to facilitate the characterization of new small molecules</scope> .</sentence>
<sentence id="3">To test this , we subjected multiple Arabidopsis thaliana accessions to chemical genetic screens and discovered 12 accession-selective hit molecules .</sentence>
<sentence id="4">As a model for understanding this variation , we characterized natural resistance to hypostatin , a new inhibitor of cell expansion .</sentence>
<sentence id="5">Map-based cloning identified HYR1 , a UDP glycosyltransferase ( UGT ) , as causative for hypostatin resistance .</sentence>
<sentence id="6">Multiple lines of evidence demonstrate that HYR1 glucosylates hypostatin in vivo to form a bioactive glucoside .</sentence>
<sentence id="7">Additionally , we delineated a HYR1 substrate motif and used it to identify another molecule modulated by glucosylation .</sentence>
<sentence id="8">Our results demonstrate that natural variation can be exploited to inform the biology of new small molecules , and that UGT sequence variation affects xenobiotic sensitivity across biological kingdoms .</sentence>